Compare ResMed Inc. (RMD) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vital Farms Inc — how do they compare? ResMed Inc. trades at $223.62 (market cap $32.61B), while Vital Farms Inc trades at $11.53 (market cap $496.50M). The key difference: ResMed Inc. is far larger — about 65.7× Vital Farms Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| RMD | VITL | |
|---|---|---|
Market Cap | $32.61B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $293.73 | $52.41 |
52-Week Low | $182.82 | $8.28 |
Enterprise Value | $31.97B | $583.51M |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
VITL trades at $11.35, down 0.8% daily, with a bearish technical signal driven by moving averages. Recent Q2 2026 results showed a loss of $0.47 per share, beating expectations but reflecting revenue declines amid industry oversupply challenges. The company secured a $125 million term loan in August 2026 to bolster liquidity, as net cash flow remained negative. Valuation ratios like P/E of 11.77 and P/S of 0.67 suggest potential undervaluation, but profitability metrics are weak with net income margin at 0.02%.
The outlook is mixed: analyst consensus is bullish with a $13.00 price target, but execution risks from cost pressures and competitive gaps persist. Near-term catalysts include Q3 2026 earnings, while downside risks involve ongoing operational challenges and class-action litigation noted in May 2026. The stock's proximity to its 52-week low underscores cautious sentiment despite institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
